Jung, Su Young
Hwang, Sunjin
Clarke, Jeffery M.
Bauer, Todd M.
Keedy, Vicki L.
Lee, Hukeun
Park, Neunggyu
Kim, Seong-Jin
Lee, Jangik I. http://orcid.org/0000-0002-5565-8323
Funding for this research was provided by:
MedPacto, Inc.
Article History
Received: 27 May 2019
Accepted: 5 July 2019
First Online: 13 July 2019
Compliance with ethical standards
:
: JIL has received research funding from MedPacto, Inc. as an advisory consultant. JMC, TMB, and VLK received grant from MedPacto, Inc. to perform of the phase 1 clinical trial as principal investigators. JMC has received research grant as a principal investigator from Bristol-Myers Squibb, Eli Lilly, Genentech, Spectrum, Adaptimmune, Medpacto, Bayer, AbbVie, and Moderna, and served as an advisory consultant for AstraZeneca, Guardant, Merck and Eli Lilly. TMB has received research grant from Daiichi Sankyo, Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, Merck, Eli Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Onyx, Sanofi, Boehringer-Ingelheim, Astellas Pharma, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, and ARMO Biosciences. VLK is a consultant for Karyopharm Therapeutics, and has research funding from Plexxicon, Eli Lilly, Daiichi Sankyo, BioMed Valley Discoveries, Immune Design, GlaxoSmithKline, TRACON Pharma, and Advenchen Laboratories. SJK and SH are a CEO and an employee of MedPacto, Inc., respectively. Other remaining authors have nothing to disclose.
: All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consents were obtained from all individual participants enrolled in the phase 1 study.